Individual hydrogen bonds play a critical role in MHC class II:peptide interactions: Implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange

Immunological Reviews

Volumn 172, Issue , 1999, Pages 239-253

  Sant, Andrea J ^a   Beeson, Craig ^b   McFarland, Benjamin ^b   Cao, Jun ^a   Ceman, Stephanie ^a,d   Bryant, Paula Wolf ^c   Wu, Shenhong ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ANTIGEN BINDING; ARTICLE; CRYSTAL STRUCTURE; HYDROGEN BOND; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 0033429414     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01369.x     Document Type: Article

References (78)

1. 1. Brown J, et al. Three-dimensional structure of the human Class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-39.
2. 2. Stern L, Wiley D. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell 1992;68:465-477.
3. 3. Jardetzky TS, et al. Crystallographic analysis of endogenous peptides associated with HLA-DRI suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci USA 1996;93:734-738.
4. 4. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-462.
5. 5. Fremont DH, Hendrickson WA, Marrack P, Kappler J. Structures of an MHC class II molecule with covalently bound single peptides. Science 1996;272:1001-1004.
6. d-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 1998;8:319-329.
7. k in complex with a dominant epitope of lysozyme. Immunity 1998;8:305-17.
8. 8. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693-708.
9. 9. Bjorkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-511.
10. 10. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 a resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992;70:1035-1048.
11. 11. Stern LJ, Wiley DC. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 1994;15:245-251.
12. 12. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995;13:587-622.
13. 13. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 1992;257:927-934.
14. 14. Griffith IJ, et al. Structural mutation affecting intracellular transport and cell surface expression of murine class II molecules. J Exp Med 1988;167:541-555.
15. 15. Chervonsky AC, Gordon L, Sant AJ. A segment of the MHC class II β chain plays a critical role in targeting class II molecules to the endocytic pathway. Int Immunol 1994;6:973-982.
16. 16. Dayhoff MO, Schwartz RM, Orcutt BC. A model of evolutionary change in proteins. In: Dayhoff MO, ed. Atlas of protein sequence and structure. Vol 5 Suppl 3. Washington DC: National Biomedical Research Foundation; 1978.
17. 17. Tan LJ, Ceman S, Rodriques-Paris J, Steck T, Sant AJ. Late events in the biogenesis of MHC class II molecules are controlled by the 80-82 segment of the class II β chain. Eur J Immunol 1997;27:1479-1488.
18. 18. Peterson M, Miller J. Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41. Nature 1992;357:596-598.
19. 19. Momburg F, et al. Epitope-specific enhancement of antigen presentation by invariant chain. J Exp Med 1993;178:1453-1458.
20. 10. Hill CM, et al. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J Immunol 1994;152:2890-2898.
21. k α-chain required for the binding and stability of two antigenic peptides. J Immunol 1996;156:176-182.
22. 22. Bijlmaker MJ, Benaroch P, Ploegh H. Assembly of HLA-DR molecules translated in vitro: binding of peptide in the endoplasmic reticulum precludes association with invariant chain. EMBO J 1994;13:2629-2707.
23. d. Science 1992;256:1817-1820.
24. 24. Germain RN. Binding domain regulation of MHC class II molecule assembly, trafficking, fate and function. Semin Immunol 1995;7:361-372.
25. 19-51. J Immunol 1996;156:3815-3820.
26. 26. Nelson CA, Petzold SJ, Unanue ER. Identification of two distinct properties of class II major histocompatibility complex associated peptides. Proc Natl Acad Sci USA 1993;90:1227-1231.
27. d mutant molecules is reflected in their peptide binding properties. Eur J Immunol (In press).
28. 28. Pamer E, Cresswell P. Mechanisms of MHC class I-restriced antigen processing. Annu Rev Immunol 1998;16:323-358.
29. 29. Riberdy J, Newcomb J, Surman M, Barbosa J, Cresswell P. HLA-DR molecules from an antigen processing mutant cell line are associated with invariant chain peptides. Nature 1992;360:474-477.
30. 30. Sette A, et al. Invariant chain peptides in most HLA-DR molecules of an antigen processing mutant. Science 1992;258:1801-1804.
31. 31. Sette A, Southwood S, Miller J, Appella E. Binding of MHC class II to the invariant chain derived peptide, CLIP, is regulated by allelic polymorphisms in class II. J Exp Med 1995;181:677-683.
32. 32. Liang MN, Beeson C, Mason K, McConnell HM. Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC. Im Immunol 1995;7:1397-1404.
33. 33. Ceman S, Wu S, Jardetzky T, Sant AJ. Alteration of a single hydrogen bond between class II and peptide results in rapid degradation of classs II after Ii removal. J Exp Med 1998;188:2139-2149.
34. 34. Anderson M, Miller J. Invariant chain can function as a chaperone protein for class II major histocompatability complex molecules. Proc Natl Acad Sci USA 1992;89:2282-2286.
35. 35. Layet C, Germain R. Invariant chain promotes egress of poorly expressed, haplotype-mismatched class II major histocompatibility complex AαAβ dimers from the endoplasmic reticulum/cis-Golgi compartment. Proc Natl Acad Sci USA 1991;88:2346-2350.
36. + T cell selection in mice lacking invariant chain expression. J Exp Med 1993;177:1699-1712.
37. 37. Viville S, et al. Mice lacking the MHC class II-associated invariant chain. Cell 1993;72:635-648.
38. 38. Sadegh-Nasseri S, Germain RN. A role for peptide in determining MHC class II structure. Nature 1991;353:167-170.
39. 39. Germain RN, Rinker AG. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 1993;363:725-728.
40. 40. Sant A, Miller J. MHC class II antigen processing: biology of invariant chain. Curr Opin Immunol 1994;6:57-63.
41. 41. Cresswell P. Invariant chain structure and MHC class II function. Cell 1996;84:505-507.
42. 42. Reyes V, Lu S, Humphreys R. Cathepsin B cleavage of Ii from class II MHC α-and β chains. J Immunol 1991;146:3877-3880.
43. 43. Marks M, Cresswell P. Invariant chain associates with HLA class II antigens via its extracytoplasmic region. J Immunol 1986;136:2519-2525.
44. 44. Wettstein D, Boniface J, Reay P, Schild H, Davis M. Expression of a class II major histocompatibility complex (MHC) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH J Exp Med 1991;174:219-228.
45. 45. Nelson CA, Petzold SJ, Unanue ER. Peptides determine the life span of MHC class II molecules in the antigen-presenting cell. Nature 1994;371:250-252.
46. 46. Germain R, Hendrix L. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 1991;353:134-139.
47. 47. Metlay J, Witmer-Pack MD, Agger R, Crowley M, Lawless D, Steinman R. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med 1990;171:1753-1771.
48. 48. Steinman R, Nogeueira N, Witmer D, Typings JD, Mellman IS. Lymphokine enhances the expression and synthesis of Ia antigens on cultured mouse peritoneal macrophages. J Exp Med 1980;152:1248-1257.
49. 49. Bhattacharya A, Dorf M, Springer T. A shared alloantigenic determinant on Ia antigens encoded by the I-A and I-E subregions: evidence for an I region gene duplication. J Immunol 1981;127:2488-2495.
50. 50. Dang L, Lien L, Benacerraf B, Rock K. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation. J Immunol 1993;150:4206-4217.
51. 51. Stebbins CC, Loss GE, Elias CG, Chervonsky A, Sant AJ. The requirement for DM in class II restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med 1995;181:223-234.
52. 52. Kappler J, Skidmore B, White J, Marrack P. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. J Exp Med 1981;153:1198-1214.
53. 53. Ozato K, Sachs D. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J Immunol 1981;126:317-321.
54. 54. Ozato K, Mayer N, Sachs D. Monoclonal antibodies to mouse major histocompatibility complex antigens. Transplantation 1982;34:113-120.
55. 55. Chervonsky AV, Medzhitov RM, Denzin LK, Barlow AK, Rudensky AY, Janeway CA. Subtle conformational changes induced in major histocompatibility complex class II molecules by binding peptides. Proc Natl Acad Sci USA 1998;95:10094-10099.
56. 56. Braunstein N, Germain R, Loney K, Berkowitz N. Structurally interdependent and independent regions of allelic polymorphism in class II MHC molecules. J Immunol 1990;145:1635-1645.
57. 57. Cole NB, Eleenberg J, Song J, DiEuliis D, Lippincott-Schwartz J. Retrograde transport of Golgi-localized proteins in the ER J Cell Biol 1998;140:1-15.
58. 58. Thery C, et al. MHC class II transport from lysosomal compartments to the cell surface is determined by stable peptide binding, but not by the cytosolic domains of the α and β-chains. J Immunol 1998;161:2106-2113.
59. 59. Rabinowitz JD, et al. Formation of a highly peptide receptive state of class II MHC. Immunity 1998;9:699-709.
60. 60. Natarajan SK, Assadi M, Sadegh-Nasseri S. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J Immunol 1999;162:4030-4036.
61. 61. McFarland BJ, Beeson C, Sant AJ. A single essential hydrogen bond controls the stability of peptide-MHC class II complexes. J Immunol (In press).
62. 62. Busch R, Mellins E. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr Opin Immunol 1996;8:51-58.
63. 63. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990;343:71-76.
64. 64. Morris P, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatability molecules. Nature 1994;368:551-554.
65. 65. Ceman S, Rudersdorf RA, Petersen JM, DeMars R. DMA and DMB are the only genes in the class II region of the human MHC needed for class II-associated antigen processing. J Immunol 1995;154:2545-2556.
66. 66. Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994;368:554-558.
67. 67. Sloan VS, et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
68. 68. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995;82:155-165.
69. 69. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 1995;3:197-205.
70. 70. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity 1996;4:87-96.
71. 71. Weber SA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996;274:618-620.
72. 72. Van Ham SM, Gruneberg U, Malcherek G, Broker I, Melms A, Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med 1996;184:2019-2024.
73. 73. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996;15:6144-6154.
74. 74. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997;6:293-302.
75. 75. Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA 1996;93:9724-9729.
76. 76. Vogt AB, Kropshofer H, Hämmerling GJ. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Hum Immunol 1997;54:170-179.
77. 77. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 1998;9:377-383.
78. 78. Guerra CB, et al. Novel glycosylation of HLA-DRα disrupts antigen presentation without altering endosomal localization. J Immunol 1998;160:4289-4297.